Innovent Biologics (HK:1801)
:1801
Want to see HK:1801 full AI Analyst Report?
Top Page
Innovent Biologics
(1801)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$78.00
▼(-14.75% Downside)
Action:Reiterated
Date:05/30/26
The score is supported primarily by the strong 2025 financial turnaround (profitability, higher margins, and sharply improved free cash flow) and a conservative balance sheet. It is held back by a weak-to-neutral technical setup (below key moving averages with negative MACD) and a very high P/E that implies a rich valuation.
Positive Factors
2025 Financial Turnaround
A clear 2025 inflection with revenue growth, positive net income and large free cash flow materially improves the company’s ability to fund R&D, commercial scale-up and manufacturing without relying on dilutive financing. Sustained cash profitability would de-risk the biotech growth model over the medium term.
Negative Factors
Modest Net Margin & Profitability Durability
Although 2025 shows positive net income, the net margin remains modest and the company has a multi-year history of operating losses. This raises risk that profitability is sensitive to product mix, pricing, or reimbursement shifts, and that the 2025 improvement may require repeatable execution to be durable.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Financial Turnaround
A clear 2025 inflection with revenue growth, positive net income and large free cash flow materially improves the company’s ability to fund R&D, commercial scale-up and manufacturing without relying on dilutive financing. Sustained cash profitability would de-risk the biotech growth model over the medium term.
Read all positive factors
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$130.98B
Dividend YieldN/A
Average Volume (3M)16.11M
Price to Earnings (P/E)133.0
Beta (1Y)0.65
Revenue Growth38.55%
EPS GrowthN/A
CountryHK
Employees5,659
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.50
Shares Outstanding1,738,237,200
10 Day Avg. Volume15,175,046
30 Day Avg. Volume16,110,837
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$120.85Price Target Upside32.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.36
Revenue Forecast (FY)HK$18.57B
Innovent Biologics Business Overview & Revenue Model
Company Description
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encomp...
How the Company Makes Money
Innovent primarily makes money by selling prescription biologic drugs in China through its commercialization platform. Revenue is generated from product sales of its marketed medicines to hospitals and other healthcare channels, with performance d...
Innovent Biologics Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
76
Positive
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.04B | 9.42B | 6.21B | 4.56B | 4.27B |
| Gross Profit | 10.00B | 7.91B | 4.40B | 3.63B | 3.70B |
| EBITDA | 1.31B | -480.28M | -660.68M | -1.75B | -2.37B |
| Net Income | 813.57M | -94.63M | -1.03B | -2.18B | -2.73B |
Balance Sheet | |||||
| Total Assets | 37.36B | 21.60B | 20.63B | 17.59B | 16.24B |
| Cash, Cash Equivalents and Short-Term Investments | 18.24B | 7.88B | 10.97B | 9.17B | 9.02B |
| Total Debt | 2.82B | 2.83B | 3.62B | 3.23B | 2.50B |
| Total Liabilities | 17.20B | 8.48B | 8.10B | 6.86B | 5.91B |
| Stockholders Equity | 19.36B | 13.12B | 12.53B | 10.73B | 10.33B |
Cash Flow | |||||
| Free Cash Flow | 9.32B | -418.39M | -1.24B | -3.30B | -3.87B |
| Operating Cash Flow | 10.00B | 1.29B | 147.81M | -1.92B | -2.02B |
| Investing Cash Flow | -6.51B | -1.17B | -998.66M | -1.44B | -2.70B |
| Financing Cash Flow | 4.73B | -606.63M | 2.59B | 2.89B | 5.00B |
Innovent Biologics Technical Analysis
Negative
91.50
Price Trends
83.05
Negative
83.52
Negative
86.91
Negative
Market Momentum
-2.14
Negative
43.17
Neutral
59.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1801, the sentiment is Negative. The current price of 91.5 is above the 20-day moving average (MA) of 76.89, above the 50-day MA of 83.05, and above the 200-day MA of 86.91, indicating a bearish trend. The MACD of -2.14 indicates Negative momentum. The RSI at 43.17 is Neutral, neither overbought nor oversold. The STOCH value of 59.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1801.
Innovent Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$40.84B | 4.17 | 38.96% | 0.95% | 95.27% | 304.20% | |
61 Neutral | HK$130.98B | 132.98 | 4.82% | ― | 38.55% | ― | |
61 Neutral | HK$33.34B | 35.73 | 23.99% | ― | 16.65% | 0.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$60.53B | 49.36 | 42.27% | ― | 80.08% | ― | |
46 Neutral | HK$76.41B | -60.61 | -14.26% | ― | 44.03% | -108.83% | |
42 Neutral | HK$30.87B | -46.82 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1801
Innovent Biologics
76.50
-5.60
-6.82%
HK:1530
3SBio
16.43
-6.04
-26.88%
HK:9926
Akeso, Inc.
85.50
-12.10
-12.40%
HK:9995
RemeGen Co. Ltd. Class H
66.85
2.35
3.64%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.25
-6.75
-29.35%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
62.75
11.40
22.20%
Innovent Biologics Corporate Events
Innovent’s Gastric Cancer ADC Wins China Priority Review After Phase 3 Success
Jun 4, 2026
Innovent Biologics said its antibody-drug conjugate arcotatug tavatecan (IBI343), targeting CLDN18.2, met the primary endpoint in an international phase 3 trial for heavily pretreated advanced gastric and gastroesophageal junction adenocarcinoma. ...
Innovent Biologics Sets June 2026 AGM With Share Buyback and Issuance Mandates on Agenda
May 29, 2026
Innovent Biologics has convened its annual general meeting for June 24, 2026 in Suzhou, where shareholders will review the company’s audited financial statements for 2025 and vote on the re-election of three directors, including one executiv...
Innovent Strikes Up to US$10.5 Billion Global Oncology Pact With Pfizer
May 28, 2026
Innovent Biologics has entered a global strategic licensing and collaboration agreement with Pfizer to research and develop 12 early-stage and de novo cancer medicines, including antibody-drug conjugates and multi-specific antibodies. The partners...
Innovent Biologics Makes USD690 Million Structured Note Investments With JPMorgan and UBS
May 22, 2026
Innovent Biologics has entered into a series of investments in structured notes issued by J.P. Morgan Structured Products B.V. and UBS, totaling USD690 million in notional and principal amounts. These include the acquisition of JPM Notes I for USD...
Innovent Wins China Approval for TYVYT–ELUNATE Combo in Advanced Kidney Cancer
May 21, 2026
Innovent Biologics said China’s National Medical Products Administration has approved the combination of its PD-1 inhibitor TYVYT (sintilimab injection) with ELUNATE (fruquintinib) for patients with locally advanced or metastatic renal cell ...
Innovent Biologics Posts 50% Revenue Surge and Advances Global Pipeline in Q1 2026
Apr 29, 2026
Innovent Biologics reported that its product revenue exceeded RMB3.8 billion in the first quarter of 2026, marking year-on-year growth of more than 50% and highlighting the success of its dual-engine strategy across oncology and general biomedicin...
Innovent Biologics Grants New Share Options and Restricted Shares Under 2024 Scheme
Mar 31, 2026
Innovent Biologics has granted 1,935,642 share options to 66 grantees, including directors and senior management, and 10,241,272 restricted shares to 1,308 grantees under its 2024 Share Scheme, with options exercisable at HK$86.10 per share over a...
Innovent Biologics Hits Record Revenue and Turns Profitable in 2025
Mar 26, 2026
Innovent Biologics reported a sharp rise in 2025 revenue to RMB13.04 billion, a 38.4% year-on-year increase that set a new scale benchmark in China’s biopharmaceutical sector. The performance was underpinned by its dual-engine portfolio stra...
Innovent Confirms Lilly Collaboration Effective, Denies Acquisition Rumors
Mar 24, 2026
Innovent Biologics has confirmed that its previously announced strategic collaboration agreement with Eli Lilly to advance novel oncology and immunology medicines has become effective as of March 24, 2026, after receiving early clearance from the ...
Innovent Biologics Sets March Board Meeting to Approve 2025 Results and Mull Dividend
Mar 12, 2026
Innovent Biologics has scheduled a board meeting for March 26, 2026 to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The board will also consider recommending a final dividend, a de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.